Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: Meta analysis of individual patient data

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Poynard, Thierry ^a   Lassailly, Guillaume ^b   Diaz, Emmanuel ^c   Clement, Karine ^a,d,e   Caïazzo, Robert ^b   Tordjman, Joan ^a,d,e   Munteanu, Mona ^f   Perazzo, Hugo ^a   Demol, Bernard ^c   Callafe, Robert ^c   Pattou, François ^b   Charlotte, Frederic ^a   Bedossa, Pierre ^g   Mathurin, Philippe ^b   Ratziu, Vlad ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Centre hospitalier Béthune   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f Biopredictive   (France)

^g BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METABOLISM; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREVALENCE; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; ANALYTICAL EQUIPMENT; FIBROSIS; LIVER CIRRHOSIS; MORBID OBESITY; PATHOLOGY;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; LIVER CIRRHOSIS; MALE; OBESITY, MORBID; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; ROC CURVE;

EID: 84858224449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030325     Document Type: Article

References (34)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, et al. (2006) Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355: 763-778.
2. Teli MR, Day CP, Burt AD, Bennett MK, James OF, (1995) Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346: 987-990.
3. Day CP, James OF, (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845.
4. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, et al. (2000) Liver fibrosis in overweight patients. Gastroenterology 118: 1117-1123.
5. Manning DS, Afdhal NH, (2008) Diagnosis and quantitation of fibrosis. Gastroenterology 134: 1670-1681.
6. Halfon P, Munteanu M, Poynard T, (2008) FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 32: 22-39.
7. Castera L, Pinzani M, (2010) Non-invasive assessment of liver fibrosis: are we ready? Lancet 375: 1419-1420.
8. Castera L, (2008) Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab 34: 674-679.
9. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, et al. (2006) Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology 6: 6.
10. Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, et al. (2011) Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 23: 499-506.
11. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, et al. (2005) The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 4: 10.
12. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, et al. (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of NASH in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6: 34.
13. FLIP consortium website Project Number: 241762 Available: http://ec.europa.eu/research/health/medical-research/severe-chronic-diseases/projects/flip_en.html Accessed 2011 Dec 26.
14. Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, et al. (2008) Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol 32: 8-21.
15. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, et al. (2007) Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 53: 1615-1622.
16. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, et al. (2008) How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 54: 1372-1378.
17. Poynard T, Munteanu M, Ngo Y, Castera L, Halfon P, et al. (2010) ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Gastroenterol Clin Biol 34: 388-396.
18. Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, et al. (2011) Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterol 11: 39.
19. Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, et al. (2008) Concordance in a world without a gold standard: A new non-invasive methodology for improving accuracy of fibrosis markers. Plos One 3: e 3857.22.
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
21. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, et al. (2003) A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38: 257-265.
22. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898-1906.
23. Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, et al. (2007) External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One 2: e1350.
24. Diaz E, Available: http://www.snfge.asso.fr/01-Bibliotheque/0B-Conferences-Flash/2008/170/indexConf.asp Accessed 2011 Dec 26.
25. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, et al. (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 95: 2892-2896.
26. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, et al. (2009) Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137: 532-540.
27. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Zvibel I, et al. (2008) Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48: 1791-1798.
28. Poynard T, Lebray P, Ingiliz P, Varaud A, Varsat B, et al. (2010) Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 10: 40.
29. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075.
30. Estep JM, Birerdinc A, Younossi Z, (2010) Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med 10: 166-172.
31. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, et al. (2006) A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 52: 1887-1896.
32. Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, et al. (2008) An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibrotest-Actitest) and viral load. PlosOne 3: e2573.
33. Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, et al. (2009) Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49: 97-105.
34. Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, et al. (2011) Relative performances of FibroTest, Fibroscan and biopsy for assessing the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol 2011 Sep 1 [Epub ahead of print].